Skip to content

Study · Observational study · n = 1,094 · 2024

4 results

Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study.

Santos LB, Mizubuti GB, da Silva LM, Silveira SQ, Nersessian RSF, Abib ACV, Bellicieri FN, Lima HO, Ho AM, Dos Anjos GS, de Moura DTH, de Moura EGH, Vieira JE

Journal of clinical anesthesia30 Oct 2024Cited by 28 (Europe PMC)

PMID39476514 (opens in a new tab)DOI10.1016/j.jclinane.2024.111668 (opens in a new tab)PepBankPUB-39476514
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studySafety outcome

    In adults having esophagogastroduodenoscopy under sedation, increased residual gastric content was more frequent in recent semaglutide users than in non-users.

    In plain wordsIn adults having a stomach scope under sedation, recent semaglutide users more often had food or fluid left in the stomach than non-users.

    Peptide
    Semaglutide
    Outcome
    IncreaseIncreased residual gastric content (RGC) at EGD
    Study

    n = 1,094

    Comparator
    Non-semaglutide group
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Increased RGC
    20.33%
    semaglutide group
    Increased RGC
    3.19%
    non-semaglutide group

    Source sentences

    Summary
    Among the 1094 (SG = 123; NSG = 971) patients included, increased RGC was observed in 56 (5.12%), being 25 (20.33%) in the SG and 31 (3.19%) in the NSG (p < 0.001).
    1 context sentence
    Summary · context
    Patients undergoing esophagogastroduodenoscopy under deep sedation/general anesthesia between July/2021-July/2023 were included and divided into two (SG = semaglutide, NSG = non-semaglutide) groups, according to whether they had received semaglutide within 30 days prior to the esophagogastroduodenoscopy.
  2. 02HumanObservational studySafety outcome

    In adults having esophagogastroduodenoscopy, stopping semaglutide less than 8 days before the procedure remained associated with increased residual gastric content after weighting.

    In plain wordsIn adults having a stomach scope, stopping semaglutide less than 8 days earlier was linked to more food or fluid left in the stomach.

    Peptide
    Semaglutide
    Outcome
    IncreaseIncreased RGC with semaglutide interruption under 8 days
    Study

    n: not reported in source

    Comparator
    Non-semaglutide group
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    OR
    10
    interruption < 8 days

    Source sentences

    Summary
    the time intervals of preoperative semaglutide interruption < 8 days [OR 10.0 (95%CI 6.67-15.65)]
    1 context sentence
    Summary · context
    Patients undergoing esophagogastroduodenoscopy under deep sedation/general anesthesia between July/2021-July/2023 were included and divided into two (SG = semaglutide, NSG = non-semaglutide) groups, according to whether they had received semaglutide within 30 days prior to the esophagogastroduodenoscopy.
  3. 03HumanObservational studySafety outcome

    In adults having esophagogastroduodenoscopy, stopping semaglutide 8-14 days before the procedure remained associated with increased residual gastric content after weighting.

    In plain wordsIn adults having a stomach scope, stopping semaglutide 8 to 14 days earlier was still linked to more food or fluid left in the stomach.

    Peptide
    Semaglutide
    Outcome
    IncreaseIncreased RGC with semaglutide interruption of 8-14 days
    Study

    n: not reported in source

    Comparator
    Non-semaglutide group
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    OR
    4.59
    interruption 8-14 days

    Source sentences

    Summary
    8-14 days [4.59 (95%CI 2.91-7.37)]
    1 context sentence
    Summary · context
    Patients undergoing esophagogastroduodenoscopy under deep sedation/general anesthesia between July/2021-July/2023 were included and divided into two (SG = semaglutide, NSG = non-semaglutide) groups, according to whether they had received semaglutide within 30 days prior to the esophagogastroduodenoscopy.
  4. 04HumanObservational studySafety outcome

    In adults having esophagogastroduodenoscopy, stopping semaglutide more than 14 days before the procedure, without digestive symptoms, showed no association with increased residual gastric content.

    In plain wordsIn adults having a stomach scope, stopping semaglutide over 14 days earlier, with no stomach symptoms, was not linked to leftover stomach contents.

    Peptide
    Semaglutide
    Outcome
    No significant changeIncreased RGC with semaglutide interruption over 14 days without digestive symptoms
    Study

    n: not reported in source

    Comparator
    Non-semaglutide group
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    OR
    0.77
    interruption > 14 days, no digestive symptoms

    Source sentences

    Summary
    Following inverse probability treatment weighting adjustment including a composite variable 'time intervals of semaglutide interruption' versus 'presence of ongoing digestive symptoms', only time intervals > 14 days and without digestive symptoms showed no association with increased RGC [OR = 0.77 (95%CI 0.22-2.01)].
    1 context sentence
    Summary · context
    Patients undergoing esophagogastroduodenoscopy under deep sedation/general anesthesia between July/2021-July/2023 were included and divided into two (SG = semaglutide, NSG = non-semaglutide) groups, according to whether they had received semaglutide within 30 days prior to the esophagogastroduodenoscopy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.